Skip NavigationSkip to Content
Return Return to Search Results

Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model

  1. Author:
    Higuchi, Takashi
    Sugisawa, Norihiko
    Miyake, Kentaro
    Oshiro, Hiromichi
    Yamamoto, Norio
    Hayashi, Katsuhiro
    Kimura, Hiroaki
    Miwa, Shinji
    Igarashi, Kentaro
    Chawla, Sant P
    Bouvet, Michael
    Singh,Shree Ram
    Tsuchiya, Hiroyuki
    Hoffman, Robert M

  2. Author Address

    AntiCancer, Inc., San Diego, CA, U.S.A., Department of Surgery, University of California, San Diego, CA, U.S.A., Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan., Sarcoma Oncology Center, Santa Monica, CA, U.S.A., Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com singhshr@mail.nih.gov tsuchi@med.kanazawa-u.ac.jp., Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan all@anticancer.com singhshr@mail.nih.gov tsuchi@med.kanazawa-u.ac.jp., AntiCancer, Inc., San Diego, CA, U.S.A. all@anticancer.com singhshr@mail.nih.gov tsuchi@med.kanazawa-u.ac.jp.,
    1. Year: 2019
    2. Date: Aug
  2. Journal: Anticancer research
    1. 39
    2. 8
    3. Pages: 4079-4084
  4. Type of Article: Article
  5. ISSN: 0250-7005
  1. Abstract:

    BACKGROUND/AIM: Recurrent osteosarcoma is a recalcitrant disease; therefore, an improved strategy is urgently needed to provide therapy. In order to develop a novel strategy for this disease, our lab has developed a patient-derived orthotopic xenograft (PDOX) mouse model for osteosarcoma. The combination of sorafenib (SFN) and palbociclib (PAL) was shown to be effective of hepatocellular carcinoma. However, whether this combination is efficacious on osteosarcoma has not been reported. The aim of this study was to determine the efficacy of the SFN and PAL combination on a cisplatinum (CDDP)-resistant osteosarcoma PDOX model. MATERIALS AND METHODS: Osteosarcoma PDOX models were randomly divided into five treatment groups: untreated-control, CDDP, SFN, PAL and the combination of SFN and PAL. RESULTS: Of these agents, the SFN-PAL combination significantly regressed tumor growth, and enhanced tumor necrosis with degenerative changes in the osteosarcoma PDOX. CONCLUSION: The SFN-PAL combination is an effective treatment strategy for osteosarcoma and therefore holds promise for clinical efficacy. Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.21873/anticanres.13565
  3. PMID: 31366491
  4. View record in Web of Science®
  5. WOS: 000482701400013
  6. PII : 39/8/4079

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel